AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+4.09%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$306M
AUM Growth
+$306M
(+20%)
Cap. Flow
+$17M
Cap. Flow
% of AUM
5.56%
Top 10 Holdings %
Top 10 Hldgs %
50.4%
Holding
90
New
22
Increased
26
Reduced
13
Closed
13
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$22.3M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$13.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$8.2M |
| 4 |
Krystal Biotech
KRYS
|
$6.67M |
| 5 |
Arcellx
ACLX
|
$6.23M |
Top Sells
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$12.3M |
| 2 |
Biogen
BIIB
|
$11.4M |
| 3 |
Ventyx Biosciences
VTYX
|
$3.3M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$2.97M |
| 5 |
FibroGen
FGEN
|
$2.65M |
Sector Composition
| 1 | Healthcare | 94.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Mersana Therapeutics
MRSN
$34.8M
| $3.62M | 1.02% |
+2,850,000
| New | +$3.62M |
|
27
Viking Therapeutics
VKTX
$3.02B
| $3.32M | 0.93% |
300,000
| – | – |
|
28
Spyre Therapeutics
SYRE
$1.02B
| $2.97M | 0.83% |
242,297
-4,657,703
| -95% | +$567K |
|
29
Dynavax Technologies
DVAX
$1.19B
| $2.95M | 0.83% |
+200,000
| New | +$2.95M |
|
30
MoonLake Immunotherapeutics
MLTX
$3.78B
| $2.85M | 0.8% |
+50,000
| New | +$2.85M |
|
31
Alkermes
ALKS
$4.95B
| $2.8M | 0.79% |
+100,000
| New | +$2.8M |
|
32
KalVista Pharmaceuticals
KALV
$713M
| $2.68M | 0.75% |
278,292
+100,000
| +56% | +$963K |
|
|
MRTX
33
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.63M | 0.74% |
+60,426
| New | +$2.63M |
|
34
Immatics
IMTX
$662M
| $2.32M | 0.65% |
200,000
-100,000
| -33% | -$1.16M |
|
35
Nuvalent
NUVL
$5.74B
| $2.3M | 0.65% |
+50,000
| New | +$2.3M |
|
|
SGEN
36
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.12M | 0.6% |
+10,000
| New | +$2.12M |
|
37
Lantheus
LNTH
$3.75B
| $2.08M | 0.59% |
+30,000
| New | +$2.08M |
|
38
Nurix Therapeutics
NRIX
$723M
| $1.97M | 0.55% |
250,000
+150,000
| +150% | +$1.18M |
|
39
Roivant Sciences
ROIV
$8.6B
| $1.75M | 0.49% |
+150,000
| New | +$1.75M |
|
40
Terns Pharmaceuticals
TERN
$651M
| $1.63M | 0.46% |
+325,000
| New | +$1.63M |
|
41
Apellis Pharmaceuticals
APLS
$3.51B
| $1.52M | 0.43% |
40,000
+30,000
| +300% | +$1.14M |
|
42
Vaxcyte
PCVX
$4.17B
| $1.27M | 0.36% |
25,000
+11,077
| +80% | +$565K |
|
43
Inspire Medical Systems
INSP
$2.53B
| $1.25M | 0.35% |
+6,293
| New | +$1.25M |
|
44
NewAmsterdam Pharma
NAMS
$2.8B
| $1.16M | 0.33% |
125,000
+25,000
| +25% | +$231K |
|
45
Tourmaline Bio
TRML
$645M
| $1.12M | 0.32% |
400,000
+200,000
| +100% | +$562K |
|
|
THRX
46
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $1.08M | 0.3% |
400,726
+160,482
| +67% | +$432K |
|
47
Milestone Pharmaceuticals
MIST
$151M
| $1.04M | 0.29% |
335,068
+35,000
| +12% | +$109K |
|
|
LIAN
48
DELISTED
LianBio American Depositary Shares
LIAN
| $1M | 0.28% |
672,357
-128,319
| -16% | -$191K |
|
49
ADC Therapeutics
ADCT
$370M
| $987K | 0.28% |
1,100,000
+500,000
| +83% | +$449K |
|
50
InflaRx
IFRX
$117M
| $969K | 0.27% |
325,097
+84,897
| +35% | +$253K |
|